Baird raised the firm’s price target on Praxis Precision (PRAX) to $76 from $73 and keeps an Outperform rating on the shares. The firm updated its model following its analyst event which suggested potential for its epilepsy drug pipeline.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision hosted investor event on clinical programs
- Praxis Precision Medicines Shares Promising EMBOLD Study Data
- Praxis Precision reports Q1 EPS ($3.29), consensus ($3.21)
- Praxis Precision sees cash runway into 2028
- Praxis Precision Medicines: Promising Epilepsy Portfolio and Upcoming Catalysts Drive Buy Rating